DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Driving and safety advice after visual-field loss

Essential points for quick revision.

!
A new field defect requires action

Sudden loss of part of the visual field can represent retinal detachment, stroke or another urgent neurological or ocular disorder. Reading a vision chart successfully does not make the person safe to drive.

Action: Arrange the appropriate emergency eye or stroke assessment and advise the person not to drive. Organise safe transport and document the advice before addressing longer-term licensing and rehabilitation.

Synopsis

Translate visual-field findings into safe driving advice, appropriate licensing notification and practical support for everyday independence.

  • Visual acuity and visual field assess different requirements for safe driving.
  • DVLA covers England, Scotland and Wales; DVA administers driver licensing in Northern Ireland.
  • A driver with a visual-field defect must notify the appropriate licensing agency.

Key red flags

Sudden persistent field loss requires urgent diagnosis even when central acuity remains normal.

Investigation priorities

01
Visual acuity and ocular examinationFirst step

Measure central function and investigate an ocular contribution.

Management branches

Immediate advicePrevent an unsafe journey

A new visual-field defect is identified or suspected during assessment.

  1. Explain that the person should not drive while the new defect is being assessed.
  2. Arrange emergency investigation where indicated and confirm a safe way home or to the receiving service.
Persistent functional lossSupport adaptation and review entitlement

A stable defect continues to affect mobility, work or confidence.

Open full textbook Answer 2 questions
Sources and review status6 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom